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Mycolyl transferaseA B S T R A C T
It is estimated that about 40% of the Indian population are infected with tuberculosis (TB)
and that 3,000,000 people die as a result of TB annually. TB is caused by Mycobacterium
tuberculosis. In 2011, the World Health Organization declared India as having the highest
TB burden worldwide. An important criteria for pathogenicity is the presence of mycolic
acid linked to the protective outer membrane of bacteria. Mycolyl transferase catalyzes
the transfer of mycolic acid and promotes cell wall synthesis. This is also considered as
a novel target for drug-mediated intervention strategies. Here, we have attempted to under-
stand the interaction between the antimicrobial peptide (AMP), dermcidin, and mycolyl
transferase in M. tuberculosis using a computational approach. The present study was
undertaken in order to elucidate the capability of AMPs to treat this bacteria, which is less
sensitive to available antibiotics, and to design a novel method for new therapies.
 2015 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Introduction
According to 2013 World Health Organization statistics for
Mycobacterium tuberculosis (MTB) in India, approximately 2.1
billion cases have been reported out of global incidences of
9 million TB cases. Such high incidences of TB in India indi-
cate a need for better health habits and food quality to pre-
vent its spread [1]. Initially, TB treatment was possible using
conventional antibiotics, however, the scenario has worsened
due to the emergence of drug-resistant MTB. The phenomena
of drug resistance began with multidrug resistant tuberculo-
sis, followed by the discovery of extensively drug-resistant
TB and total drug-resistant TB. Acquisition of resistance tomany antibiotics makes this bacterium difficult to treat [2].
MTB mostly causes lung infections, but also infects other
organs, such as the kidneys, lymph nodes, joints, vertebral
column, and even the spleen.
Mycolic acids are hydroxyl fatty acids with long alkyl side
chains. They are found in the cell wall of Mycolata taxon,
which includes MTB, and increase resistance against chemi-
cal damage and dehydration, allowing the bacteria to readily
grow inside macrophages and protect themselves against
host immune systems. Mycolic acids are crucial for bacterial
existence and maintenance of pathogenicity. MTB expresses
and secretes three closely related mycolyl transferases with
masses between 30 kDa and 35 kDa, known as antigen-85nces, Adit
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involved in the biogenesis of MTB cell walls. Given their vital
role in cell wall synthesis, they are considered an ideal target
for therapeutic treatment against TB [3]. These proteins cat-
alyze the transfer of mycolic acid from one trehalose 6-
monomycolate (TMM) to another, forming trehalose 6,6-
dimycolate (DMM) and free trehalose.
Antimicrobial peptides (AMPs) are short stretches of amino
acids made up of less than 50 amino acid residues with a
molecular weight of between 2 kDa and 12 kDa and a broad
spectrum of antimicrobial activity. AMPs can be cationic, anio-
nic, or neutral are a key component of the innate immune sys-
tem present in multicellular organisms [4]. A large number of
AMP families are produced in animals,with the twomain fam-
ilies called defensins and cathelicidins. AMPs exhibit broad
spectrum antimicrobial activity. One advantage is that
microbes do not easily gain resistance to them due to their
nonspecific binding to the cell membrane. Therefore, they
can be used to treat infections caused by organisms that are
resistant to conventional antibiotics, i.e., drug resistant. Derm-
cidin is an AMP encoded by the DCD gene (NM_001300854.1) in
humans. It is secreted by sweat gland cells to provide a barrier
function [5]. Dermcidin display a broad spectrumof antimicro-
bial activity against both Gram-positive and Gram-negative
bacterial pathogens [6]. The present study was undertaken in
order to understand the inhibitory effect of dermcidin on
mycolyl transferase by means of in silico studies.
Materials and methods
System requirements
The entire study was performed on a Sony Vaio Laptop with a
2.67 GHz processor, 4 GB RAM, and a 320 GB hard drive and a
Windows Professional operating system. All software used for
the present study were open-source tools available free for
download.
Receptor molecule fibronectin-binding protein A (FbpA)
MTBexpresses threemycolyl transferase enzymes that are clo-
sely related and together constitute anAg85 complex. They are
involved in cell wall synthesis by catalyzing the reaction
betweenTMMandmycolic acid to formDMM,also calledacord
factor, which is a structure necessary for maintaining cell wall
integrity [7]. They are also involved in transformation ofmyco-
lic acid from TMM to arabinogalactan for the peptidoglycan
layer of the cell wall, ultimately forming an arabinogalactan-
mycolate polymer [8]. The structure of mycolyl transferase,
also known as FbpA, was retrieved from the Protein Data Bank
(PDB ID: 1SFR) [9]. FbpA is an enzymewith a molecular weight
of 35.68 kDa, a pI of 6.51, and consisting of 304 amino acid resi-
dues. Data were also obtained from the tuberculist database
(http://tuberculist.epfl.ch/; RV number: 3804c) [9,10].
Ligand molecule
In the present study, dermcidin AMP was used as a ligand
molecule. Dermcidin is a peptide of 110 amino acid residues
that is cleaved by proteases present in human sweat to pro-duce peptides of varying length and diverse function. The
dermcidin C-terminal peptide possesses antibacterial and
antifungal activity and is constitutively expressed in sweat,
while the N-terminal peptide promotes survival of neural
cells under conditions of severe oxidative stress. The amino
acid sequence of the C-terminal peptide is NH2–SSLLEKGLD
GAKKAVGGLGKLGKDAVEDLESVGK–COOH and was used in
the present study to generate the protein model. The protein
model was generated using the SWISS MODEL online web
tool. (http://swissmodel.expasy.org/) [11]. SWISS MODEL is a
fully automated protein structure homology modeling server.
Based upon query coverage and a Global Model Quality Esti-
mation (GMQE) score, a template was selected to model the
protein. GMQE estimates the quality of the generated protein
model, which combines properties from the target-template
alignment [12].
Docking software
Four different docking software tools were used. Discovery
Studio 4.1 is software developed by Accelrys (Dassault Sys-
temes, BIOVIA Corp., San Diego, CA, USA) for creating small-
molecule structures, as well as macromolecules. A Molecular
Graphics Laboratory (MGL) tool (The Scripps Research Insti-
tute, La Jolla, CA, USA) was used for the visualization and
analysis of molecular structures. AutoDock (The Scripps
Research Institute) is a docking tool used to predict the inter-
action between small molecules, such as drug compounds or
substrates, with the three-dimensional structure of a mole-
cule. Docking between Mycolyl transferase (FbpA-receptor)
and dermcidin AMP (ligand) was performed using AutoDock
Vina. Docked structures were visualized using the open
source, molecular visualization system PyMol 1.7.4 (Schro¨din-
ger, LLC, Cambridge, MA, USA).
Docking protocol
The receptor and ligand molecules were prepared for docking
using Discovery Studio 4.1 [Dassault Syste`mes BIOVIA, Dis-
covery Studio Modeling Environment, Release 4.5, 2015]. FbpA
molecule was opened using Discovery Studio, after which
water molecules and other bound ligand molecules were
removed. The binding site was defined after adding hydrogen
molecules to the FbpA receptor molecule in order to describe
the receptor cavity. FbpA (receptor) and dermcidin (ligand)
molecules were saved as PDB files, then opened in the Auto-
DockTools portion of MGL 1.5.6 (The Scripps Research Insti-
tute) in order to prepare the receptor and ligand molecule
for docking. Docking was performed using AutoDock Vina




The AMP selected in the present study is dermcidin, which
was confirmed by matrix-assisted laser desorption/ionization
mass spectrometry analysis. Dermcidin is an AMP with 110
amino acid residues. Following secretion, it undergoes
Fig. 1 – Ramchandran plots for (A) 1KSG (template) and (B) modeled dermcidin molecule.
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small peptides of between 25 and 48 amino acid residues
[14]. A model of dermcidin was generated based on 100%
query coverage using the template molecule (PDB ID: 1KSG)
[15]. The generated model was validated based on parameters
mentioned in Section ‘‘Materials and methods”.
Ramchandran plot
The Ramchandran plot for the template molecule was
retrieved from the PDB and the plot for the modeled protein
was also generated. Structural evaluation was performed
using RAMPAGE (http://mordred.bioc.cam.ac.uk/~rapper/
rampage.php). Ramchandran plot analysis for the modeled
protein revealed that 98% of the residues localized within
favored regions, suggesting good quality of the model (Fig. 1).
GMQE score
The GMQE score is generated by the target-template align-
ment of the modeled protein and the value is expressed as
a number between zero and one. Higher GMQE scores indicateFig. 2 – Structural comparison of mincreased structural reliability [11]. The GMQE score for the
modeled protein was found to be 0.98, which indicates good
model accuracy.
Structural visualization
Structures of the template molecule and modeled molecules
were visualized as described in Section ‘‘Materials and meth-
ods” and compared for structural variation (Fig. 2).
Enzyme active site
The Ag85A, Ag85B, and Ag85C complexes have mycolyl trans-
ferase activity that catalyze glycolipid synthesis of the
mycobacterial cell wall, called the cord factor, and are also
known as FbpA, FbpB, and FbpC. FbpA is a trimer consisting
of three identical polypeptide chains (A, B, and C) of 304
amino acid residues each (Fig. 3A). In a previous study by Ron-
ning et al. (2004) [9], OSG-octylthioglucoside was used as a
substrate for Ag85C, given its similarity to a portion of the
AG85C natural substrate trehalose-monomycolate. They
studied the structure of Ag85C using OSG-octylthioglucosideodels (A) 1KSG and (B) model.



















A and B chains A and B chains A and B chains
1 Asp 40 16 Gln 157 31 Phe 228
2 Gly 41 17 Pro 161 32 Leu 229
3 Leu 42 18 Thr 162 33 Glu 230
4 Arg 43 19 Leu 163 34 Gly 231
5 Leu 125 20 Ile 164 35 Phe 232
6 Ser 126 21 Gly 165 36 Val 233
7 Met 127 22 Leu 166 37 Arg 234
8 Ala 128 23 Ala 167 38 Thr 235
9 Ala 129 24 Met 168 39 Ser 236
10 Ser 130 25 Gly 169 40 Asn 237
11 Ser 131 26 Asp 170 41 Ile 238
12 Ala 132 27 Leu 224 42 Lys 239
13 Leu 133 28 Pro 225 43 Phe 240
14 Thr 134 29 Ala 226 44 Gln 241
15 Asp 154 30 Lys 227 45 Asp 242
Fig. 3 – FbpA (A) mycolyl transferase (PDB ID: 1SFR) chains A, B, and C. (B) Formation of receptor cavity in mycolyl transferase
enzyme.
Table 2 – Nine poses with energy calculations and RMSD
values.





1. 5.6 0.000 0.000
2. 5.4 5.259 13.579
3. 5.4 4.139 10.959
4. 5.4 4.902 14.511
5. 5.4 7.369 14.865
6. 5.3 5.639 15.013
7. 5.3 4.414 14.524
8. 5.1 6.224 14.440
9. 5.1 5.218 14.686
RMSD = Root-mean-square deviation.
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strate binding and its interaction with the active site. Data
revealed two types of interactions taking place between
OSG-octylthioglucoside and Ag85C: van der Waals contacts
and hydrogen bonds. Trp-158, Leu-161, Ile-163, and Ala-165
are involved in van der Waals interactions between OSG-
octylthioglucoside and Ag85C. Gly-39 and Arg-41 are involved
in the formation of hydrogen bonds with the glucose moiety
of the substrate and the side chains of Asp-38, Asn-52, and
Trp-262 residues located within 5.4A˚ of the substrate, as well
as interactions with the disaccharide ring of the carbohydrate
moiety [9]. Here, FbpAwas selected as a target for ligand bind-
ing. The FbpA receptor cavity is shown in Fig. 3B. The amino
acid residues involved in formation of the receptor cavity
are shown in Table 1. Approximately 45 amino acid residues
are involved in the formation of the FbpA receptor cavity.
Over 50% of the residues have hydrophobic side chains and
are involved in hydrophobic interactions. The receptor cavity
is being formed between chains A and B (Fig. 3B), so only the
Fig. 4 – Visualization of docking between (A) FbpA and OSG-octylthioglucoside and (B) FbpA and the modeled dermcidin
molecule.
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formation.
Docking study
The docking of FbpA with dermcidin AMP was performed by
AutoDock Vina, generating nine different poses (Table 2).
The posewith best fit was selected based on having the lowest
binding energy associated with interactions with the ligand
molecule. In the present study, 5.6 kcal/mol was found to be
the lowest energy value relative to other results and, therefore,
was considered to represent the best fit model. The docked
model was visualized using PyMol (Fig. 4). FbpA binding to
dermcidin involves 13 hydrogen bonds between substrate
and FbpA residues (Table 3). Of these 13 residues, six are
involved with receptor cavity formation, confirming localiza-
tion of dermcidin binding within the receptor cavity (Table 3)
in the cleft between FbpA chains A and B (Fig. 4). FbpA docking
with OSG-octylthioglucoside displayed nine different areas of
interaction, with the lowest binding energy measured at
7.4 kcal/mol. Residues involved in interactions between FbpA
and OSG-octylthioglucoside were Leu-42, Ser-126, His-262,
and Trp-264. Of these four residues, two residues, i.e. Leu-42
and Ser-126 are located in the receptor cavity. This confirmsTable 3 – Residue interactions between receptor and ligand.













13. Asp 258the interaction of OSG-octylthioglucoside molecule with the
receptor cavity. Comparison of residues involved in receptor
cavity formation and those involved in hydrogen bonding
between FbpA and dermcidin or OSG-octylthioglucoside indi-
cated that both ligands bind in the receptor cavity. Therefore,
we can postulate that the binding of dermcidin in the receptor
cavity might affect binding of its natural substrate, mycolic
acid, and, therefore, interfere in MTB cell wall synthesis.Conclusion
The present study concludes that dermcidin binds with FbpA
to inhibit mycolic acid transfer to the peptidoglycan layer of
the cell wall, interfering with cell wall synthesis.Conflicts of interest
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